mouse anti human cd34 monoclonal antibodies Search Results


93
RayBiotech inc pe cd34
Figure 1 |ADSC culture and identity verification, and the effect of VEGF on ADSCs. (A) Representative images of ADSCs on days 3 (i) and 5 (ii) of primary culture, as well as third-passage ADSCs (iii). On day 3, the cells were spindle-shaped, isolated, scattered, and adherent. By day 5, the cells had proliferated rapidly, and the cell colonies had expanded. The morphology of the third-passage cells was uniform, displaying a characteristic fish-like, fibrous, and swirling arrangement. Scale bar: 100 μm. (B) Flow cytometric analysis of CD90, CD29, <t>CD34,</t> and CD45 expression on the cell surface of third-passage ADSCs. (C) CCK-8 analysis of the viability of ADSCs treated with different concentrations of VEGF. Data are expressed as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, vs. Cont group (one-way analysis of variance with Bonferroni’s post hoc test). (D) Enzyme-linked immunosorbent assay analysis of VEGF, b-FGF, TGF-β, BDNF, and IGF-1 concentration by ADSC cells treated with VEGF (50 ng/mL) or left untreated. Data are expressed as mean ± SEM (n = 12). **P < 0.01, ***P < 0.001, vs. VEGF- group (one-way analysis of variance with Bonferroni’s post hoc test [C] or unpaired t-test [D]). ADSCs: Adipose-derived mesenchymal stem cells; BDNF: brain-derived neurotrophic factor; b-FGF: basic fibroblast growth factor; Cont: control; IGF- 1: insulin-like growth factor-1; TGF-β: transforming growth factor-β; VEGF: vascular endothelial growth factor.
Pe Cd34, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+human+cd34+monoclonal+antibodies/Mouse+anti-Human%2FRat+CD34+Antibody+%5BPE+Conjugated%5D/10__4103_slash_nrr__nrr___d___24___00129-87-17-18
Average 93 stars, based on 1 article reviews
pe cd34 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

90
Serotech Inc cd34-fitc clone 1h6 antibody
Figure 1 |ADSC culture and identity verification, and the effect of VEGF on ADSCs. (A) Representative images of ADSCs on days 3 (i) and 5 (ii) of primary culture, as well as third-passage ADSCs (iii). On day 3, the cells were spindle-shaped, isolated, scattered, and adherent. By day 5, the cells had proliferated rapidly, and the cell colonies had expanded. The morphology of the third-passage cells was uniform, displaying a characteristic fish-like, fibrous, and swirling arrangement. Scale bar: 100 μm. (B) Flow cytometric analysis of CD90, CD29, <t>CD34,</t> and CD45 expression on the cell surface of third-passage ADSCs. (C) CCK-8 analysis of the viability of ADSCs treated with different concentrations of VEGF. Data are expressed as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, vs. Cont group (one-way analysis of variance with Bonferroni’s post hoc test). (D) Enzyme-linked immunosorbent assay analysis of VEGF, b-FGF, TGF-β, BDNF, and IGF-1 concentration by ADSC cells treated with VEGF (50 ng/mL) or left untreated. Data are expressed as mean ± SEM (n = 12). **P < 0.01, ***P < 0.001, vs. VEGF- group (one-way analysis of variance with Bonferroni’s post hoc test [C] or unpaired t-test [D]). ADSCs: Adipose-derived mesenchymal stem cells; BDNF: brain-derived neurotrophic factor; b-FGF: basic fibroblast growth factor; Cont: control; IGF- 1: insulin-like growth factor-1; TGF-β: transforming growth factor-β; VEGF: vascular endothelial growth factor.
Cd34 Fitc Clone 1h6 Antibody, supplied by Serotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+human+cd34+monoclonal+antibodies/cd34+mouse+anti+human+antibody/pmc05327053-197-10-14
Average 90 stars, based on 1 article reviews
cd34-fitc clone 1h6 antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Maxim Biotech Inc mouse anti-human cd34 monoclonal antibody
Representative images of immunohistochemical analysis of <t>CD34</t> in endometriotic lesions of the (A) control, (B) saline and (C) rapamycin-treated groups. Staining was performed with the streptomycin avidin-peroxidase method. Magnification, ×400.
Mouse Anti Human Cd34 Monoclonal Antibody, supplied by Maxim Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+human+cd34+monoclonal+antibodies/mouse+anti+human+cd34+monoclonal+antibody/pmc04907216-43-8-30
Average 90 stars, based on 1 article reviews
mouse anti-human cd34 monoclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Fuzhou Maxim Biotech mouse anti-human monoclonal cd34 antibody
CT scan and immunohistochemical staining results <t>(CD34,</t> 200×) of three cases. ( A1, A2 , a 67-year-old woman): Obvious heterogeneous contrast enhancement in the right kidney (bold arrow) with a VTA value of 160 HU and a RTV value of 1.3 was displayed. There were many microvessels which mainly consisted of relatively mature vessels with lumen (bold arrow) and the microvascular areas were the largest. ( B1, B2 , a 44-year-old man): Moderate homogeneous contrast enhancement in the left kidney (curved arrow) with a VTA value of 87 HU and a RTV value of 0.75 was displayed. Microvessels mainly consisted of vessels with fissured lumen (curved arrow) and the microvascular area was large. ( C1, C2 , a 59-year-old man): Mild contrast enhancement (long arrow) with a VTA value of 80 HU and a RTC value of 0.6 was displayed. Pseudo-capsule (short arrow) appeared as hyper density in the lesion margin. There were a few microvessels which involvement in microvessels without lumen mostly (long and short arrows) and the microvascular area was the smallest.
Mouse Anti Human Monoclonal Cd34 Antibody, supplied by Fuzhou Maxim Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+human+cd34+monoclonal+antibodies/mouse+anti+human+monoclonal+cd34+antibody/pmc05549640-102-5-15
Average 90 stars, based on 1 article reviews
mouse anti-human monoclonal cd34 antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Tektronix inc mouse anti-human cd34 class ii monoclonal antibody
CT scan and immunohistochemical staining results <t>(CD34,</t> 200×) of three cases. ( A1, A2 , a 67-year-old woman): Obvious heterogeneous contrast enhancement in the right kidney (bold arrow) with a VTA value of 160 HU and a RTV value of 1.3 was displayed. There were many microvessels which mainly consisted of relatively mature vessels with lumen (bold arrow) and the microvascular areas were the largest. ( B1, B2 , a 44-year-old man): Moderate homogeneous contrast enhancement in the left kidney (curved arrow) with a VTA value of 87 HU and a RTV value of 0.75 was displayed. Microvessels mainly consisted of vessels with fissured lumen (curved arrow) and the microvascular area was large. ( C1, C2 , a 59-year-old man): Mild contrast enhancement (long arrow) with a VTA value of 80 HU and a RTC value of 0.6 was displayed. Pseudo-capsule (short arrow) appeared as hyper density in the lesion margin. There were a few microvessels which involvement in microvessels without lumen mostly (long and short arrows) and the microvascular area was the smallest.
Mouse Anti Human Cd34 Class Ii Monoclonal Antibody, supplied by Tektronix inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+human+cd34+monoclonal+antibodies/mouse+anti+human+cd34+class+ii+monoclonal+antibody/pm21161731-27-39-47
Average 90 stars, based on 1 article reviews
mouse anti-human cd34 class ii monoclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier


N/A
MOUSE ANTI HUMAN CD34 CLASS II:RPE; MOUSE ANTI HUMAN CD34 CLASS II:RPE
  Buy from Supplier

N/A
Mouse anti-Human/Rat CD34 Antibody
  Buy from Supplier

N/A
Mouse anti-Human/Rat CD34 Antibody [PE Conjugated]
  Buy from Supplier

N/A
Mouse anti-Human CD34 Antibody Cocktail [IHC only]
  Buy from Supplier

N/A
Mouse anti-Human CD34 Antibody Cocktail [IHC only]
  Buy from Supplier

N/A
Mouse anti-Human/Rat CD34 Antibody
  Buy from Supplier

Image Search Results


Figure 1 |ADSC culture and identity verification, and the effect of VEGF on ADSCs. (A) Representative images of ADSCs on days 3 (i) and 5 (ii) of primary culture, as well as third-passage ADSCs (iii). On day 3, the cells were spindle-shaped, isolated, scattered, and adherent. By day 5, the cells had proliferated rapidly, and the cell colonies had expanded. The morphology of the third-passage cells was uniform, displaying a characteristic fish-like, fibrous, and swirling arrangement. Scale bar: 100 μm. (B) Flow cytometric analysis of CD90, CD29, CD34, and CD45 expression on the cell surface of third-passage ADSCs. (C) CCK-8 analysis of the viability of ADSCs treated with different concentrations of VEGF. Data are expressed as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, vs. Cont group (one-way analysis of variance with Bonferroni’s post hoc test). (D) Enzyme-linked immunosorbent assay analysis of VEGF, b-FGF, TGF-β, BDNF, and IGF-1 concentration by ADSC cells treated with VEGF (50 ng/mL) or left untreated. Data are expressed as mean ± SEM (n = 12). **P < 0.01, ***P < 0.001, vs. VEGF- group (one-way analysis of variance with Bonferroni’s post hoc test [C] or unpaired t-test [D]). ADSCs: Adipose-derived mesenchymal stem cells; BDNF: brain-derived neurotrophic factor; b-FGF: basic fibroblast growth factor; Cont: control; IGF- 1: insulin-like growth factor-1; TGF-β: transforming growth factor-β; VEGF: vascular endothelial growth factor.

Journal: Neural Regeneration Research

Article Title: A vascular endothelial growth factor–loaded chitosanhyaluronic acid hydrogel scaffold enhances the therapeutic effect of adipose-derived stem cells in the context of stroke

doi: 10.4103/nrr.nrr-d-24-00129

Figure Lengend Snippet: Figure 1 |ADSC culture and identity verification, and the effect of VEGF on ADSCs. (A) Representative images of ADSCs on days 3 (i) and 5 (ii) of primary culture, as well as third-passage ADSCs (iii). On day 3, the cells were spindle-shaped, isolated, scattered, and adherent. By day 5, the cells had proliferated rapidly, and the cell colonies had expanded. The morphology of the third-passage cells was uniform, displaying a characteristic fish-like, fibrous, and swirling arrangement. Scale bar: 100 μm. (B) Flow cytometric analysis of CD90, CD29, CD34, and CD45 expression on the cell surface of third-passage ADSCs. (C) CCK-8 analysis of the viability of ADSCs treated with different concentrations of VEGF. Data are expressed as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, vs. Cont group (one-way analysis of variance with Bonferroni’s post hoc test). (D) Enzyme-linked immunosorbent assay analysis of VEGF, b-FGF, TGF-β, BDNF, and IGF-1 concentration by ADSC cells treated with VEGF (50 ng/mL) or left untreated. Data are expressed as mean ± SEM (n = 12). **P < 0.01, ***P < 0.001, vs. VEGF- group (one-way analysis of variance with Bonferroni’s post hoc test [C] or unpaired t-test [D]). ADSCs: Adipose-derived mesenchymal stem cells; BDNF: brain-derived neurotrophic factor; b-FGF: basic fibroblast growth factor; Cont: control; IGF- 1: insulin-like growth factor-1; TGF-β: transforming growth factor-β; VEGF: vascular endothelial growth factor.

Article Snippet: The following fluorochrome-labeled antibodies were utilized: APC-cy7-CD45 (BD Biosciences, San Jose, CA, USA, Cat# 561586, RRID: AB_10896305), PE-CD34 (RayBiotech, Norcross, GA, USA, Cat# 188-10041-PE, RRID: AB_2315728), FITC-CD90 (BD Biosciences, Cat# 561973, RRID: AB_395588), and BV421-CD29 (BD Biosciences, Cat# 564131, RRID: AB_2738613).

Techniques: Isolation, Expressing, CCK-8 Assay, Enzyme-linked Immunosorbent Assay, Concentration Assay, Derivative Assay, Control

Representative images of immunohistochemical analysis of CD34 in endometriotic lesions of the (A) control, (B) saline and (C) rapamycin-treated groups. Staining was performed with the streptomycin avidin-peroxidase method. Magnification, ×400.

Journal: Experimental and Therapeutic Medicine

Article Title: Effect of rapamycin on endometriosis in mice

doi: 10.3892/etm.2016.3280

Figure Lengend Snippet: Representative images of immunohistochemical analysis of CD34 in endometriotic lesions of the (A) control, (B) saline and (C) rapamycin-treated groups. Staining was performed with the streptomycin avidin-peroxidase method. Magnification, ×400.

Article Snippet: Mouse anti-human VEGF (1:200; cat. no. RB-9031) and CD34 (1:100; cat. no. MS-363) monoclonal antibodies, streptomycin avidin-peroxidase (SP) immunochemistry (cat. no. Kit-9701) and DAB (cat. no. Kit-0017) kits were from Maxim Biotech, Inc. (Fuzhou, China).

Techniques: Immunohistochemical staining, Control, Saline, Staining, Avidin-Biotin Assay

CT scan and immunohistochemical staining results (CD34, 200×) of three cases. ( A1, A2 , a 67-year-old woman): Obvious heterogeneous contrast enhancement in the right kidney (bold arrow) with a VTA value of 160 HU and a RTV value of 1.3 was displayed. There were many microvessels which mainly consisted of relatively mature vessels with lumen (bold arrow) and the microvascular areas were the largest. ( B1, B2 , a 44-year-old man): Moderate homogeneous contrast enhancement in the left kidney (curved arrow) with a VTA value of 87 HU and a RTV value of 0.75 was displayed. Microvessels mainly consisted of vessels with fissured lumen (curved arrow) and the microvascular area was large. ( C1, C2 , a 59-year-old man): Mild contrast enhancement (long arrow) with a VTA value of 80 HU and a RTC value of 0.6 was displayed. Pseudo-capsule (short arrow) appeared as hyper density in the lesion margin. There were a few microvessels which involvement in microvessels without lumen mostly (long and short arrows) and the microvascular area was the smallest.

Journal: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

Article Title: Relative Computed Tomography (CT) Enhancement Value for the Assessment of Microvascular Architecture in Renal Cell Carcinoma

doi: 10.12659/MSM.902957

Figure Lengend Snippet: CT scan and immunohistochemical staining results (CD34, 200×) of three cases. ( A1, A2 , a 67-year-old woman): Obvious heterogeneous contrast enhancement in the right kidney (bold arrow) with a VTA value of 160 HU and a RTV value of 1.3 was displayed. There were many microvessels which mainly consisted of relatively mature vessels with lumen (bold arrow) and the microvascular areas were the largest. ( B1, B2 , a 44-year-old man): Moderate homogeneous contrast enhancement in the left kidney (curved arrow) with a VTA value of 87 HU and a RTV value of 0.75 was displayed. Microvessels mainly consisted of vessels with fissured lumen (curved arrow) and the microvascular area was large. ( C1, C2 , a 59-year-old man): Mild contrast enhancement (long arrow) with a VTA value of 80 HU and a RTC value of 0.6 was displayed. Pseudo-capsule (short arrow) appeared as hyper density in the lesion margin. There were a few microvessels which involvement in microvessels without lumen mostly (long and short arrows) and the microvascular area was the smallest.

Article Snippet: Tissue sections were stained using mouse anti-human monoclonal CD34 antibody and goat anti-mouse polyclonal antibody (Fuzhou Maxim Biotechnology Co. Ltd., Fuzhou, China) using the streptavidin-peroxidase method, following the instructions provided by the company.

Techniques: Computed Tomography, Immunohistochemical staining, Staining